title: Megakaryocyte-related interleukins in reactive thrombocytosis versus autonomous thrombocythemia.
abstract: The primary thrombocytosis (thrombocythemia) associated with myeloproliferative disorders is believed to be due to autonomous platelet production. Secondary or reactive thrombocytosis can be observed in a number of clinical circumstances, and may be related to persistent overproduction of some thrombocytopoietic factors acting on megakaryocytes. Several cytokines, including IL-6, IL-1 and IL-4 have been shown to act alone or in concert, to affect various cellular stages of megakaryocytopoiesis in humans. The aim of this study is to assess the serum concentrations of these cytokines in myeloproliferative disorders (MPD) with thrombocythemia and in rheumatoid arthritis (RA) with marked reactive thrombocytosis. Twenty-two patients (14 men, 8 women) with MPD and thrombocythemia (platelet counts > 500 x 10(9)/1; range 507-996 x 10(9)/1), 33 RA patients (28 women, 5 men) with marked thrombocytosis (platelet counts > 500 x 10(9)/1; range 500-745 x 10(9)/ 1), 27 RA patients (24 women, 3 men) with normal platelet counts (range 168-399 x 10(9)/1) and 15 healthy volunteers (8 women, 7 men) with normal platelet counts (range 161-385 x 10(9)/1) enrolled in the study. Serum IL-1 alpha, IL-1 beta, IL-4 and IL-6 concentrations were measured in these four groups. Of the 22 patients with MPD, 10 had chronic myelogenous leukemia, 5 had polycythemia vera, 6 had essential thrombocytosis and 1 had osteomyelofibrosis. Serum interleukin concentrations in patients with MPD and thrombocythemia were either suppressed or similar to those of normal subjects, whereas IL-6, IL-1 beta and IL-4 levels were increased in RA patients with reactive thrombocytosis. We conclude that thrombocythemia associated with MPD is an autonomous phenomenon, and is not regulated by cytokines which affect megakaryocytopoiesis.
authors.affiliation: Department of Hematology, Hacettepe University Medical School, Ankara, Turkey.
authors.forename: I C
authors.initials: IC
authors.lastname: Haznedaroğlu
authors.forename: I
authors.initials: I
authors.lastname: Ertenli
authors.forename: O I
authors.initials: OI
authors.lastname: Ozcebe
authors.forename: S
authors.initials: S
authors.lastname: Kiraz
authors.forename: O
authors.initials: O
authors.lastname: Ozdemir
authors.forename: N M
authors.initials: NM
authors.lastname: Sayinalp
authors.forename: S V
authors.initials: SV
authors.lastname: Dündar
authors.forename: M
authors.initials: M
authors.lastname: Calgüneri
authors.forename: S
authors.initials: S
authors.lastname: Kirazli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000150:complications; D005260:Female; D006410:Hematopoiesis; D006801:Humans; D007378:Interleukins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood*; D013922:Thrombocytosis / Q000209:etiology*
chemical_list: D007378:Interleukins